All In Biotech

Drug Trial Radar · NCT06525350

A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel(Albumin Bound)Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer

A Randomized, Controlled, Open-label Phase Ⅱ Study to Evaluate the Safety, Tolerability, and Efficacy of the Combination of Glumetinib Tablets and Docetaxel for Injection(Albumin Bound)Verse Docetaxel in the Treatment of Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer Patients With MET Overexpression

Last checked: Nov 20, 2026Latest source record: Jul 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 256 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

256

Planned (sponsor's estimate)

Start

Jul 2024

Primary completion

Dec 25, 2026

Study completion Jun 25, 2028

Sponsor

Sponsor type
Industry
First posted
Jul 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (randomized controlled study). The main purpose of Stage 1 is to preliminarily evaluate the safety and tolerability of the combination of glumetinib Tablets and Docetaxel for Injection(Albumin Bound)(HB1801) in the treatment of MET-overexpressed non-small cell lung cancer (NSCLC); The main purpose of Stage 2 is to evaluate the efficacy of the combination of glumetinib tablets and HB1801 compared to glumetinib tablets monotherapy or docetaxel in the treatment of MET-expressed NSCLC.

Conditions

  • Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression

Interventions

  • Glumetinib tabletsDrug

    An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor

  • HB1801 (docetaxel, albumin-bound)Drug

    An improved new formulations of docetaxel

  • DocetaxelDrug

    A chemotherapy drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity(DLT) occurrence and incidenceTime frame: Up to approximately 48 months after the first participant is enrolled
  2. Recommended phase 2 dose(RP2D) of the combination therapyTime frame: Up to approximately 48 months after the first participant is enrolled
  3. Adverse events (AE) and serious adverse events (SAE) occurrence and incidenceTime frame: Up to approximately 48 months after the first participant is enrolled
  4. Objective response rate (ORR) per RECIST 1.1Time frame: Up to approximately 48 months after the first participant is enrolled

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.